Business Context and Reporting Period
This Form 8-K is filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on November 8, 2024, reporting the entry into a material definitive agreement. The registrant is a Delaware corporation with its principal executive offices in Boca Raton, Florida, and its common stock trades on the Nasdaq Capital Market under the symbol ENTO.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes and Transaction Details
The primary material change is the execution of a Binding Term Sheet for the acquisition of Journey Therapeutics, Inc. ("Journey"). Key terms include:
- Acquisition Structure: Entero Therapeutics will acquire 100% of Journey's outstanding equity in exchange for 99% of Entero's fully-diluted equity.
- Leadership Transition: Henry Ji, M.D., Ph.D., CEO of Journey, is anticipated to become the CEO and Chairman of the Board of the combined company.
- Board Composition: The post-closing Board size will be determined jointly, with one to two members designated by Entero.
- Equity Plans: The company anticipates adopting an equity incentive plan for up to 15% of outstanding shares and an employee stock purchase plan (ESPP) for up to 1% of outstanding shares, subject to approvals.
- Exclusivity: A minimum 30-day exclusivity period is in effect, during which neither party may solicit or negotiate with third parties regarding the sale of their businesses.
Conditions, Risks, and Outlook
The transaction is subject to several material conditions and risks:
- Financing Requirement: Completion is conditioned upon an equity financing providing net proceeds of at least $5 million.
- Regulatory and Listing: The deal requires the effectiveness of a Form S-4 Registration Statement and approval for the initial listing of the combined company's shares on Nasdaq.
- Approvals: The transaction requires customary due diligence, negotiation of a definitive agreement, and approval by Entero's Board and stockholders.
- Management Commentary: The company issued a press release on November 13, 2024, announcing the agreement, which is incorporated by reference.
Investor Verification Checklist
- Verify the final terms of the definitive agreement once negotiated.
- Confirm the successful completion of the required $5 million equity financing.
- Monitor the status of the Form S-4 Registration Statement and Nasdaq listing approval.
- Track the outcome of the stockholder vote required to approve the acquisition and new equity plans.
- Review the final composition of the post-closing Board of Directors.